- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04849091
Clinical Effectiveness of iReadMore for People With Alexia
Investigating the Clinical Effectiveness of iReadMore; a Digital Therapy for People With Alexia (Acquired Dyslexia)
iReadMore will provide an app-based therapy for people with pure or central alexia.
This study aims to test the clinical effectiveness of iReadMore for improving reading accuracy and speed in real world users of the therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
iReadMore is a self-led therapy app for improving single word reading accuracy and speed in individuals with acquired reading impairments. iReadMore has been demonstrated to improve reading speed and accuracy in pure and central alexias (Woodhead et al., 2013, 2018). iReadMore therapy is not expected to improve reading for the remaining alexia subtypes.
iReadMore includes 590 of the most frequently written words from the SUBTLEX lexical database (Brysbaert and New, 2009). High frequency words were chosen to maximise the relevance (ecological utility) of the training to everyday life. The therapy mechanism relies on mass practice of cross-modal, paired associate learning (Holcomb and Anderson, 1993) based on the Triangle Model approach to reading. Untrained words will not be affected, and thus word reading improvements are not expected to generalise beyond trained items.
The therapy utilises gamification and is designed to be accessible in order to drive motivation and engagement for the user group. iReadMore is downloadable via the Google Play store on Android tablet devices. iReadMore is a CE-marked class 1 medical device that was developed by the Neurotherapeutics Group, University College London.
An online roll-out trial will be conducted to evaluate the clinical effectiveness of iReadMore with a study population of real world users. The therapy will be evaluated in a clinical population with a reading impairment of any acquired cause (such as stroke or brain injury). Participants will self-enrol in the study through the app, which has been co-designed to ensure accessibility to this user group.
A within-participant evaluation of trained versus untrained items will investigate the clinical effectiveness of the therapy for improving reading speed and accuracy. The primary outcomes are improvements in single word reading accuracy and speed. Interval testing will be conducted after every 5 hours of therapy. The secondary outcomes are self-reported Activities of Daily Living and a series of qualitative questions.
Further analyses will be conducted on alexia subtypes and the influence of therapy dose and intensity on the therapeutic outcomes.
Ethical approval for the iReadMore roll-out trial was obtained from the UCL Research Ethics Committee (ID: 7609/001).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Alexander P Leff, Professor
- Phone Number: 02076791177
- Email: a.leff@ucl.ac.uk
Study Contact Backup
- Name: Thomas Langford, MSc
- Phone Number: 07972267097
- Email: thomas.langford.18@ucl.ac.uk
Study Locations
-
-
-
London, United Kingdom, WC1N 3AR
- Recruiting
- Institute of Neurology, University College London
-
Sub-Investigator:
- Zoe Woodhead, PhD, MSc
-
Sub-Investigator:
- Jenny Crinion, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Over 18 years old
- Diagnosed with stroke, dementia, brain injury or brain tumour
- Diagnosed or self-diagnosed with impaired reading ability
- Willing and able to give informed consent for participation in the study
Exclusion Criteria:
- History of developmental reading or speech and language disability
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
iReadMore users
Participants will be iReadMore users who completed a baseline reading test between XX/XX/XXXX and XX/XX/XXXX, and who performed at least 5 hours of reading training and a second (interval) reading test. iReadMore users will self-register to participate in the study. |
Digital Alexia Therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Word Reading Test - Change in Reading Accuracy and Speed from baseline to 20 hours
Time Frame: At baseline and after every 5 hours of therapy up to a maximum dose of 50 hours. Primary outcome is change from baseline to 20 hours.
|
Change in single word reading accuracy and speed will be assessed in a Word Reading Test (WRT) delivered in the app.
At interval tests, the WRT will include both trained and untrained words to investigate the treatment-specific effects.
|
At baseline and after every 5 hours of therapy up to a maximum dose of 50 hours. Primary outcome is change from baseline to 20 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant-Reported Outcome Measures - Activities of Daily Living (ADL)
Time Frame: At baseline and after every 10 hours of therapy up to a maximum dose of 50 hours
|
Activities of Daily Living - Participants are asked to rate how easy they find completing a series of everyday tasks, including language and non-language related tasks.
Responses are reported using a 7-point Likert scale from 0 to 6 denoting 'Very Easy' to 'Very Hard'.
|
At baseline and after every 10 hours of therapy up to a maximum dose of 50 hours
|
Participant-Reported Outcome Measures - Qualitative Questions
Time Frame: At baseline and after every 10 hours of therapy up to a maximum dose of 50 hours
|
Qualitative Questions - participants are also asked three open text questions on their experiences of the therapy and their reading abilities at that point in time.
|
At baseline and after every 10 hours of therapy up to a maximum dose of 50 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexander P Leff, Professor, University College, London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Neurobehavioral Manifestations
- Craniocerebral Trauma
- Trauma, Nervous System
- Neurodevelopmental Disorders
- Language Disorders
- Communication Disorders
- Learning Disabilities
- Speech Disorders
- Brain Injuries
- Dyslexia
- Aphasia
Other Study ID Numbers
- 7609/001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium